Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace.

Original title: “Lilly takes oral obesity race abroad with UK launch of Foundayo”

Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.

Original title: “Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug”

The Phase 3 study is evaluating two doses of Novo’s Wegovy pill in people with obesity or overweight in combination with a reduced-calorie diet and increased physical activity.

Original title: “Novo Nordisk starts trialing lower maintenance doses of oral Wegovy”

trends in utilization of glucagon like peptide 1 receptor agonists sodium glucose cotransporter 2 inhibitors and metabolic bariatric surgery in u s adults with diabetes and obesity

Original title: “Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. Adults with diabetes and obesity.”

Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.

Original title: “Enveda’s exercise-simulating obesity tablet clears early clinical test”

Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.

Original title: “Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?”

A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.

Original title: “Amylyx’s bet on a GLP-1 blocker pays off”

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

Original title: “Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide”

Beyond the legal action, Eli Lilly is calling on healthcare providers, regulatory authorities, online platforms and even logistics companies to help stem the illegal sale of its next-generation asset for weight loss.

Original title: “Lilly cracks down on black market for obesity asset retatrutide with six lawsuits”

impact of premature mortality attributable to obesity on years of life lost in brazil

Original title: “Impact of premature mortality attributable to obesity on years of life lost in Brazil.”

A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

Original title: “Lilly, FDA retatrutide biologic dispute comes to a head as submission nears”

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

Original title: “Lilly climbs, Novo falls as obesity drug battle intensifies”

Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.

Original title: “Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A”

The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.

Original title: “Lilly and Resilience invest $750M in diabetes and obesity drug device supply”

The expansion will create 400 jobs dedicated to making GLP-1 injectables across Resilience’s contract manufacturing facilities.

Original title: “Resilience and Lilly invest $750M to boost Cincinnati drug production”

rethinking obesity management targets findings from an international moscow prioritization workshop

Original title: “Rethinking obesity management targets: Findings from an international MoSCoW prioritization workshop.”

Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”

Original title: “Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court”

'We now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea.' The results from the TRIUMPH-2 and TRIUMPH-3 studies provide a clinical data package to support global regulatory submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. The clinical data package will support global submissions for the drug as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. “Across five positive phase 3 studies, retatrutide has shown powerful efficacy, and we believe it could be an important future tool in the management of cardiometabolic health,” says Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health, in a release. “With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. In the TRIUMPH-3 trial, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks on the highest dose. The study also found that major adverse cardiovascular events occurred less frequently in participants taking retatrutide compared to the placebo group.

Original title: “Phase 3 Trials Show Weight Loss for Triple Agonist with OSA Potential | Sleep Review”

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

Original title: “Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma”

beyond monogenic obesity the unmet need for anti obesity pharmacotherapy in rare genetic syndromes

Original title: “Beyond monogenic obesity: the unmet need for anti-obesity pharmacotherapy in rare genetic syndromes.”